The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children.
Identifieur interne : 002586 ( PubMed/Checkpoint ); précédent : 002585; suivant : 002587The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children.
Auteurs : S M Graham [Australie] ; M. Grzemska [Suisse] ; R P Gie [Afrique du Sud]Source :
- The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease [ 1815-7920 ] ; 2015.
Descripteurs français
- KwdFr :
- Antituberculeux (administration et posologie), Association de médicaments, Enfant, Guides de bonnes pratiques cliniques comme sujet, Humains, Isoniazide (administration et posologie), Organisation mondiale de la santé, Poids du corps, Pyrazinamide (administration et posologie), Rifampicine (administration et posologie), Tuberculose (traitement médicamenteux), Éthambutol (administration et posologie).
- MESH :
- administration et posologie : Antituberculeux, Isoniazide, Pyrazinamide, Rifampicine, Éthambutol.
- traitement médicamenteux : Tuberculose.
- Association de médicaments, Enfant, Guides de bonnes pratiques cliniques comme sujet, Humains, Organisation mondiale de la santé, Poids du corps.
English descriptors
- KwdEn :
- Antitubercular Agents (administration & dosage), Body Weight, Child, Drug Therapy, Combination, Ethambutol (administration & dosage), Humans, Isoniazid (administration & dosage), Practice Guidelines as Topic, Pyrazinamide (administration & dosage), Rifampin (administration & dosage), Tuberculosis (drug therapy), World Health Organization.
- MESH :
- chemical , administration & dosage : Antitubercular Agents, Ethambutol, Isoniazid, Pyrazinamide, Rifampin.
- drug therapy : Tuberculosis.
- Body Weight, Child, Drug Therapy, Combination, Humans, Practice Guidelines as Topic, World Health Organization.
Abstract
In 2010, the World Health Organization revised the recommendations for the treatment of tuberculosis (TB) in children. The major revision was to increase isoniazid, rifampicin and pyrazinamide dosages according to body weight in children. The recommendations for higher dosages are based on consistent evidence from 1) pharmacokinetic studies suggesting that young children require higher dosages than adolescents and adults to achieve desired serum concentrations; and 2) observational studies reporting that the higher dosages would not be associated with increased risk of toxicity in children. However, national tuberculosis programmes faced unforeseen challenges in implementing the revised recommendations. The main difficulty was to adapt the revised dosages for the treatment of children with drug-susceptible TB using available fixed-dose combinations (FDCs). A more suitable FDC for the intensive and continuation phases of treatment has now been developed for planned implementation in 2015. This paper explains the background and rationale for the development of a new FDC tablet for children with drug-susceptible TB.
DOI: 10.5588/ijtld.15.0416
PubMed: 26564534
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26564534Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children.</title><author><name sortKey="Graham, S M" sort="Graham, S M" uniqKey="Graham S" first="S M" last="Graham">S M Graham</name><affiliation wicri:level="1"><nlm:affiliation>Centre for International Child Health, University of Melbourne Department of Paediatrics and Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Victoria, Australia; International Union Against Tuberculosis and Lung Disease, Paris, France; The Burnet Institute, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Centre for International Child Health, University of Melbourne Department of Paediatrics and Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Victoria, Australia; International Union Against Tuberculosis and Lung Disease, Paris, France; The Burnet Institute, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Grzemska, M" sort="Grzemska, M" uniqKey="Grzemska M" first="M" last="Grzemska">M. Grzemska</name><affiliation wicri:level="1"><nlm:affiliation>Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Global Tuberculosis Programme, World Health Organization, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Gie, R P" sort="Gie, R P" uniqKey="Gie R" first="R P" last="Gie">R P Gie</name><affiliation wicri:level="1"><nlm:affiliation>Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Children's Hospital, Cape Town, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Children's Hospital, Cape Town</wicri:regionArea><wicri:noRegion>Cape Town</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26564534</idno><idno type="pmid">26564534</idno><idno type="doi">10.5588/ijtld.15.0416</idno><idno type="wicri:Area/PubMed/Corpus">002605</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002605</idno><idno type="wicri:Area/PubMed/Curation">002536</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002536</idno><idno type="wicri:Area/PubMed/Checkpoint">002536</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002536</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children.</title><author><name sortKey="Graham, S M" sort="Graham, S M" uniqKey="Graham S" first="S M" last="Graham">S M Graham</name><affiliation wicri:level="1"><nlm:affiliation>Centre for International Child Health, University of Melbourne Department of Paediatrics and Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Victoria, Australia; International Union Against Tuberculosis and Lung Disease, Paris, France; The Burnet Institute, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Centre for International Child Health, University of Melbourne Department of Paediatrics and Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Victoria, Australia; International Union Against Tuberculosis and Lung Disease, Paris, France; The Burnet Institute, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Grzemska, M" sort="Grzemska, M" uniqKey="Grzemska M" first="M" last="Grzemska">M. Grzemska</name><affiliation wicri:level="1"><nlm:affiliation>Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Global Tuberculosis Programme, World Health Organization, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Gie, R P" sort="Gie, R P" uniqKey="Gie R" first="R P" last="Gie">R P Gie</name><affiliation wicri:level="1"><nlm:affiliation>Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Children's Hospital, Cape Town, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Children's Hospital, Cape Town</wicri:regionArea><wicri:noRegion>Cape Town</wicri:noRegion></affiliation></author></analytic><series><title level="j">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</title><idno type="eISSN">1815-7920</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antitubercular Agents (administration & dosage)</term><term>Body Weight</term><term>Child</term><term>Drug Therapy, Combination</term><term>Ethambutol (administration & dosage)</term><term>Humans</term><term>Isoniazid (administration & dosage)</term><term>Practice Guidelines as Topic</term><term>Pyrazinamide (administration & dosage)</term><term>Rifampin (administration & dosage)</term><term>Tuberculosis (drug therapy)</term><term>World Health Organization</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antituberculeux (administration et posologie)</term><term>Association de médicaments</term><term>Enfant</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Isoniazide (administration et posologie)</term><term>Organisation mondiale de la santé</term><term>Poids du corps</term><term>Pyrazinamide (administration et posologie)</term><term>Rifampicine (administration et posologie)</term><term>Tuberculose (traitement médicamenteux)</term><term>Éthambutol (administration et posologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antitubercular Agents</term><term>Ethambutol</term><term>Isoniazid</term><term>Pyrazinamide</term><term>Rifampin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antituberculeux</term><term>Isoniazide</term><term>Pyrazinamide</term><term>Rifampicine</term><term>Éthambutol</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tuberculose</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Body Weight</term><term>Child</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Practice Guidelines as Topic</term><term>World Health Organization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association de médicaments</term><term>Enfant</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Organisation mondiale de la santé</term><term>Poids du corps</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In 2010, the World Health Organization revised the recommendations for the treatment of tuberculosis (TB) in children. The major revision was to increase isoniazid, rifampicin and pyrazinamide dosages according to body weight in children. The recommendations for higher dosages are based on consistent evidence from 1) pharmacokinetic studies suggesting that young children require higher dosages than adolescents and adults to achieve desired serum concentrations; and 2) observational studies reporting that the higher dosages would not be associated with increased risk of toxicity in children. However, national tuberculosis programmes faced unforeseen challenges in implementing the revised recommendations. The main difficulty was to adapt the revised dosages for the treatment of children with drug-susceptible TB using available fixed-dose combinations (FDCs). A more suitable FDC for the intensive and continuation phases of treatment has now been developed for planned implementation in 2015. This paper explains the background and rationale for the development of a new FDC tablet for children with drug-susceptible TB.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26564534</PMID><DateCreated><Year>2015</Year><Month>11</Month><Day>13</Day></DateCreated><DateCompleted><Year>2016</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1815-7920</ISSN><JournalIssue CitedMedium="Internet"><Volume>19 Suppl 1</Volume><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</Title><ISOAbbreviation>Int. J. Tuberc. Lung Dis.</ISOAbbreviation></Journal><ArticleTitle>The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children.</ArticleTitle><Pagination><MedlinePgn>3-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5588/ijtld.15.0416</ELocationID><Abstract><AbstractText>In 2010, the World Health Organization revised the recommendations for the treatment of tuberculosis (TB) in children. The major revision was to increase isoniazid, rifampicin and pyrazinamide dosages according to body weight in children. The recommendations for higher dosages are based on consistent evidence from 1) pharmacokinetic studies suggesting that young children require higher dosages than adolescents and adults to achieve desired serum concentrations; and 2) observational studies reporting that the higher dosages would not be associated with increased risk of toxicity in children. However, national tuberculosis programmes faced unforeseen challenges in implementing the revised recommendations. The main difficulty was to adapt the revised dosages for the treatment of children with drug-susceptible TB using available fixed-dose combinations (FDCs). A more suitable FDC for the intensive and continuation phases of treatment has now been developed for planned implementation in 2015. This paper explains the background and rationale for the development of a new FDC tablet for children with drug-susceptible TB.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>S M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Centre for International Child Health, University of Melbourne Department of Paediatrics and Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Victoria, Australia; International Union Against Tuberculosis and Lung Disease, Paris, France; The Burnet Institute, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grzemska</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gie</LastName><ForeName>R P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Children's Hospital, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Int J Tuberc Lung Dis</MedlineTA><NlmUniqueID>9706389</NlmUniqueID><ISSNLinking>1027-3719</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2KNI5N06TI</RegistryNumber><NameOfSubstance UI="D011718">Pyrazinamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>8G167061QZ</RegistryNumber><NameOfSubstance UI="D004977">Ethambutol</NameOfSubstance></Chemical><Chemical><RegistryNumber>V83O1VOZ8L</RegistryNumber><NameOfSubstance UI="D007538">Isoniazid</NameOfSubstance></Chemical><Chemical><RegistryNumber>VJT6J7R4TR</RegistryNumber><NameOfSubstance UI="D012293">Rifampin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004977" MajorTopicYN="N">Ethambutol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007538" MajorTopicYN="N">Isoniazid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011718" MajorTopicYN="N">Pyrazinamide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012293" MajorTopicYN="N">Rifampin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="N">Tuberculosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26564534</ArticleId><ArticleId IdType="doi">10.5588/ijtld.15.0416</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Afrique du Sud</li><li>Australie</li><li>Suisse</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Graham, S M" sort="Graham, S M" uniqKey="Graham S" first="S M" last="Graham">S M Graham</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Grzemska, M" sort="Grzemska, M" uniqKey="Grzemska M" first="M" last="Grzemska">M. Grzemska</name></noRegion></country><country name="Afrique du Sud"><noRegion><name sortKey="Gie, R P" sort="Gie, R P" uniqKey="Gie R" first="R P" last="Gie">R P Gie</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002586 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002586 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26564534
|texte= The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26564534" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |